Artelo Biosciences (NASDAQ:ARTL) Earns Buy Rating from D. Boral Capital

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $6.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 417.24% from the stock’s previous close.

ARTL has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Artelo Biosciences in a research report on Monday, December 9th. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a research note on Wednesday, December 25th. Finally, EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st.

Artelo Biosciences Trading Up 1.8 %

NASDAQ ARTL opened at $1.16 on Tuesday. The stock has a market cap of $3.74 million, a P/E ratio of -0.40 and a beta of 1.25. Artelo Biosciences has a 12 month low of $0.91 and a 12 month high of $1.75. The stock’s fifty day moving average price is $1.09 and its 200-day moving average price is $1.19.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. As a group, analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.